Edwards Lifesciences/$EW
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Edwards Lifesciences
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
Ticker
$EW
Sector
Primary listing
NYSE
Employees
15,800
Headquarters
Website
EW Metrics
BasicAdvanced
$49B
36.09
$2.33
0.97
-
Price and volume
Market cap
$49B
Beta
0.97
52-week high
$87.09
52-week low
$64.89
Average daily volume
4.9M
Financial strength
Current ratio
4.004
Quick ratio
2.982
Long term debt to equity
6.6
Total debt to equity
6.624
Interest coverage (TTM)
81.81%
Profitability
EBITDA (TTM)
1,776.3
Gross margin (TTM)
78.19%
Net profit margin (TTM)
23.25%
Operating margin (TTM)
27.53%
Effective tax rate (TTM)
14.99%
Revenue per employee (TTM)
$370,000
Management effectiveness
Return on assets (TTM)
7.72%
Return on equity (TTM)
13.49%
Valuation
Price to earnings (TTM)
36.089
Price to revenue (TTM)
8.39
Price to book
4.78
Price to tangible book (TTM)
6.51
Price to free cash flow (TTM)
61.738
Free cash flow yield (TTM)
1.62%
Free cash flow per share (TTM)
1.362
Growth
Revenue change (TTM)
10.60%
Earnings per share change (TTM)
-66.20%
3-year revenue growth (CAGR)
3.13%
10-year revenue growth (CAGR)
9.20%
3-year earnings per share growth (CAGR)
0.15%
10-year earnings per share growth (CAGR)
12.72%
What the Analysts think about EW
Analyst ratings (Buy, Hold, Sell) for Edwards Lifesciences stock.
Bulls say / Bears say
In Q1 2025, transcatheter mitral and tricuspid therapies (TMTT) sales surged 58% year-over-year to $115 million, driven by robust adoption of the PASCAL and EVOQUE systems alongside CE Mark approval of SAPIEN M3 and a finalized Medicare NCD that broadens patient access to EVOQUE. (Business Wire)
In Q4 2024, Edwards Lifesciences’ revenue grew 9.4% year-over-year to $1.39 billion, fueled by an 87.7% surge in its TMTT segment to $105.1 million, surpassing analyst expectations and lifting shares over 4% in after-hours trading. (Investing.com)
During Q3 2025, TAVR sales climbed 12.4% to $1.15 billion, catalyzing a “halo effect” that boosted total sales nearly 15% and prompted management to raise full-year sales growth guidance to the high end of 9%-10% and EPS guidance to $2.56-$2.62. (Investor’s Business Daily)
The U.S. FTC filed a lawsuit to block Edwards’ $1.2 billion JenaValve acquisition, arguing the deal would stifle competition in the TAVR market, potentially delaying integration and increasing litigation costs. (Reuters)
Edwards announced CFO Scott Ullem will step down by mid-2026 and remain in an advisory role, introducing potential leadership transition risks as the company searches for his successor amid key M&A and growth initiatives. (Reuters)
On November 4, 2025, Edwards Lifesciences’ shares rose 1.30% but underperformed industry peers such as Abbott and Medtronic during a broadly negative trading session, highlighting the stock’s vulnerability to sector headwinds. (MarketWatch)
Data summarised monthly by Lightyear AI. Last updated on 11 Nov 2025.
EW Financial Performance
Revenues and expenses
EW Earnings Performance
Company profitability
EW News
AllArticlesVideos
Edwards Champions American Heart Association Initiative to Reduce Deaths, Improve Care for Patients With Heart Valve Disease
Business Wire2 days ago
Edwards Lifesciences beats quarterly estimates on strength in heart devices
Reuters2 weeks ago
Edwards Lifesciences CFO Scott Ullem to step down by mid-2026
Reuters2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Edwards Lifesciences stock?
Edwards Lifesciences (EW) has a market cap of $49B as of November 11, 2025.
What is the P/E ratio for Edwards Lifesciences stock?
The price to earnings (P/E) ratio for Edwards Lifesciences (EW) stock is 36.09 as of November 11, 2025.
Does Edwards Lifesciences stock pay dividends?
No, Edwards Lifesciences (EW) stock does not pay dividends to its shareholders as of November 11, 2025.
When is the next Edwards Lifesciences dividend payment date?
Edwards Lifesciences (EW) stock does not pay dividends to its shareholders.
What is the beta indicator for Edwards Lifesciences?
Edwards Lifesciences (EW) has a beta rating of 0.97. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.